BioNTech (NASDAQ:BNTX) CEO Sells $3,520,080.00 in Stock

BioNTech SE Sponsored ADR (NASDAQ:BNTX) CEO Ugur Sahin sold 36,000 shares of the business’s stock in a transaction on Wednesday, September 9th. The stock was sold at an average price of $97.78, for a total value of $3,520,080.00. Following the completion of the transaction, the chief executive officer directly owned 708,709 shares of the company’s stock, valued at approximately $69,297,566.02. This trade represents a 4.83% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Ugur Sahin also recently made the following trade(s):

• On Thursday, September 10th, Ugur Sahin sold 20,500 shares of BioNTech stock. The shares were sold at an average price of $96.31, for a total value of $1,974,355.00.
• On Tuesday, September 8th, Ugur Sahin sold 37,000 shares of BioNTech stock. The shares were sold at an average price of $99.20, for a total value of $3,670,400.00.
• On Friday, September 4th, Ugur Sahin sold 31,500 shares of BioNTech stock. The stock was sold at an average price of $103.52, for a total value of $3,260,880.00.
• On Thursday, September 3rd, Ugur Sahin sold 45,000 shares of BioNTech stock. The stock was sold at an average price of $102.85, for a total value of $4,628,250.00.

BioNTech Trading Up 0.3%

Shares of BNTX stock opened at $96.73 on Friday. The company has a market capitalization of $24.46 billion, a price-to-earnings ratio of -12.35 and a beta of 1.29. The company has a current ratio of 7.85, a quick ratio of 7.80 and a debt-to-equity ratio of 0.01. The firm has a 50-day moving average price of $96.98 and a 200 day moving average price of $95.38. BioNTech SE Sponsored ADR has a twelve month low of $79.52 and a twelve month high of $124.00.

BioNTech (NASDAQ:BNTX) last released its quarterly earnings results on Tuesday, August 4th. The company reported ($2.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.40) by ($0.13). The firm had revenue of $122.31 million for the quarter, compared to analyst estimates of $180.18 million. BioNTech had a negative return on equity of 6.86% and a negative net margin of 63.54%.BioNTech’s revenue for the quarter was down 59.5% on a year-over-year basis. During the same period in the prior year, the business earned ($1.60) earnings per share. Research analysts forecast that BioNTech SE Sponsored ADR will post -6.33 earnings per share for the current fiscal year.

Hedge Funds Weigh In On BioNTech

A number of large investors have recently bought and sold shares of BNTX. Engineers Gate Manager LP boosted its holdings in shares of BioNTech by 17.3% in the 2nd quarter. Engineers Gate Manager LP now owns 12,433 shares of the company’s stock valued at $1,157,000 after purchasing an additional 1,833 shares during the last quarter. Integrated Wealth Concepts LLC acquired a new stake in shares of BioNTech during the 2nd quarter worth $39,000. Nykredit A S purchased a new position in shares of BioNTech in the 2nd quarter worth $293,000. B. Metzler seel. Sohn & Co. AG raised its position in shares of BioNTech by 66.7% in the 2nd quarter. B. Metzler seel. Sohn & Co. AG now owns 10,967 shares of the company’s stock worth $1,020,000 after buying an additional 4,390 shares during the period. Finally, Headlands Technologies LLC acquired a new position in BioNTech in the second quarter valued at $2,520,000. Hedge funds and other institutional investors own 15.52% of the company’s stock.

Analysts Set New Price Targets

BNTX has been the subject of several recent analyst reports. Jefferies Financial Group reaffirmed a “buy” rating on shares of BioNTech in a research note on Monday, June 1st. Weiss Ratings restated a “sell (d-)” rating on shares of BioNTech in a report on Monday, July 6th. Wall Street Zen downgraded BioNTech from a “hold” rating to a “sell” rating in a research report on Saturday, August 8th. Canaccord Genuity Group dropped their target price on BioNTech from $142.00 to $136.00 and set a “buy” rating for the company in a research note on Monday, August 31st. Finally, Morgan Stanley reduced their target price on BioNTech from $126.00 to $119.00 and set an “overweight” rating on the stock in a research report on Wednesday, July 8th. One analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $126.00.

About BioNTech

BioNTech SE is a biotechnology company focused on developing immunotherapies and vaccines for cancer and other serious diseases. Its research platforms include messenger RNA, cell therapies, protein-based therapeutics, antibody therapies and small-molecule immunomodulators.

The company is best known for Comirnaty, its COVID-19 vaccine developed and commercialized globally in collaboration with Pfizer. BioNTech is also advancing a broad oncology pipeline that includes individualized and off-the-shelf cancer vaccines, antibody-based treatments, cell therapies and combination approaches designed to stimulate or direct the immune system against tumors.

BioNTech was founded in 2008 and is headquartered in Mainz, Germany.